BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 02-May-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on May 06, 2021 at 1:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.

SQURPHARMA 31-Jan-2021

(Q2 Un-audited): The Company has further informed that Consolidated EPS was Tk. 4.33 instead of 4.18 for October-December 2020 as against Tk. 3.98 instead of Tk. 3.70 for October-December 2019. All other information will remain unchanged.

SQURPHARMA 31-Jan-2021

(Q2 Un-audited): Consolidated EPS was Tk. 4.18 for October-December 2020 as against Tk. 3.70 for October-December 2019; Consolidated EPS was Tk. 8.76 for July-December 2020 as against Tk. 7.77 for July-December 2019. Consolidated NOCFPS was Tk. 7.28 for July-December 2020 as against Tk. 5.60 for July-December 2019. Consolidated NAV per share was Tk. 92.47 as on December 31, 2020 and Tk. 87.28 as on June 30, 2020.

SQURPHARMA 24-Jan-2021

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders.

SQURPHARMA 24-Jan-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.

SQURPHARMA 24-Dec-2020

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2020; unaudited financials up to September 30, 2020 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

SQURPHARMA 23-Dec-2020

The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2020 to the respective shareholders' BO Accounts on December 23, 2020.

SQURPHARMA 22-Nov-2020

Trading of the shares of the Company will resume on 23.11.2020 after record date.

SQURPHARMA 18-Nov-2020

(Continuation news of SQURPHARMA): Note 8- SHORT TERM LOAN (Unsecured): Balance of Short Term Loan (Unsecured) as at 30 June 2020 was BDT 4,885,090,120 and as at 30 June 2019 was BDT 2,937,071,066. This loan consists of loan given to Square Textiles Ltd, Square Fashions Ltd., Square Hospitals Ltd., Square Lifesciences Ltd.(end)

SQURPHARMA 18-Nov-2020

The auditor of the Square Pharmaceuticals Ltd has given the "Emphasis of Matter " paragraph in the Auditor's Report for the year ended on 30 June 2020. Emphasis of Matter: We draw attention to the note no. 8 to the separate financial statements, which describes the loans given to subsidiaries and associates as well as companies with common directors. The company obtained approval for such loans from the Board of Directors. Our opinion is not modified in this regard. (cont.)

Previous Next page